Jennewein Biotechnologie

News and Press Announcements


20.11.2017 EU approval for 2′-fucosyllactose

The Jennewein Biotechnologie GmbH received a response from the European Commission which includes the decision that “2′-fucosyllactose powder and liquid concentrate may be placed on the European Union market as a novel food ingredient.”  This follows a decision by the Committee on Safety Assessment of Novel Foods (VNV) to issue a certificate in September 2016 stating that the Jennewein product is “…a well-characterized 2′-fucosyllactose preparation of high purity.” The VNV based its notification on European Commission Regulation 258/97 and a dossier provided by Jennewein Biotechnologie containing specific technical information about the product. This confirms that Jennewein’s 2′-fucosyllactose, which is produced using a bacterial fermentation process, is the first HMO to receive a novel food authorization under EU law and can now enter the market in Europe. The registration of this HMO will revolutionize the EU infant formula market.:“This Novel Food authorization is a milestone in the history of biotechnology, and a major breakthrough in the development of infant formula,” stated Stefan Jennewein, the CEO of Jennewein Biotechnologie GmbH.